TY - JOUR
T1 - Targeting the temporal dynamics of hypoxia-induced tumor-secreted factors halts tumor migration
AU - Singh, Manjulata
AU - Tian, Xiao Jun
AU - Donnenberg, Vera S.
AU - Watson, Alan M.
AU - Zhang, Jing Yu
AU - Stabile, Laura P.
AU - Watkins, Simon C.
AU - Xing, Jianhua
AU - Sant, Shilpa
N1 - Funding Information:
We thank Dr. Wen Xie, University of Pittsburgh School of Pharmacy, for providing access to the core facilities. We thank Drs. Barry Gold and Vinayak Sant, Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, for critical reading and insightful suggestions on the manuscript. This work is supported by the Department of Pharmaceutical Sciences, School of Pharmacy University of Pittsburgh (SS), NIH (grant no. R37CA232209 to S. Sant, J. Xing, V.S. Donnenberg, S.C. Watkins); the National Science Foundation (grant no. DMS-1462049 to J. Xing); the Pennsylvania Department of Health (grant no. SAP 4100062224 to J. Xing); BC032981, BC044784, W81XWH-12-1-0415, and BC132245_W81XWH-14-0258 from the Department of Defense (to V.S. Donnenberg); the Hillman Foundation (to V.S. Donnenberg); and the Glimmer of Hope Foundation (to V.S. Donnenberg). The confocal microscope in the Center for Biologic Imaging at University of Pittsburgh is UPCI supported by 1S10OD019973-01 (to S.C. Watkins). Cytometry Facility is supported by CCSG P30CA047904.
Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Targeting microenvironmental factors that foster migratory cell phenotypes is a promising strategy for halting tumor migration. However, lack of mechanistic understanding of the emergence of migratory phenotypes impedes pharmaceutical drug development. Using our three-dimensional microtumor model with tight control over tumor size, we recapitulated the tumor size–induced hypoxic microenvironment and emergence of migratory phenotypes in microtumors from epithelial breast cells and patient-derived primary metastatic breast cancer cells, mesothelioma cells, and lung cancer xenograft cells. The microtumor models from various patient-derived tumor cells and patient-derived xenograft cells revealed upregulation of tumor-secreted factors, including matrix metalloproteinase-9 (MMP9), fibronectin (FN), and soluble E-cadherin, consistent with clinically reported elevated levels of FN and MMP9 in patient breast tumors compared with healthy mammary glands. Secreted factors in the conditioned media of large microtumors induced a migratory phenotype in nonhypoxic, nonmigratory small microtumors. Subsequent mathematical analyses identified a two-stage microtumor progression and migration mechanism whereby hypoxia induces a migratory phenotype in the initialization stage, which then becomes self-sustained through a positive feedback loop established among the tumor-secreted factors. Computational and experimental studies showed that inhibition of tumor-secreted factors effectively halts microtumor migration despite tumor-to-tumor variation in migration kinetics, while inhibition of hypoxia is effective only within a time window and is compromised by tumor-to-tumor variation, supporting our notion that hypoxia initiates migratory phenotypes but does not sustain it. In summary, we show that targeting temporal dynamics of evolving microenvironments, especially tumor-secreted factors during tumor progression, can halt tumor migration. Significance: This study uses state-of-the-art three-dimensional microtumor models and computational approaches to highlight the temporal dynamics of tumor-secreted microenvironmental factors in inducing tumor migration.
AB - Targeting microenvironmental factors that foster migratory cell phenotypes is a promising strategy for halting tumor migration. However, lack of mechanistic understanding of the emergence of migratory phenotypes impedes pharmaceutical drug development. Using our three-dimensional microtumor model with tight control over tumor size, we recapitulated the tumor size–induced hypoxic microenvironment and emergence of migratory phenotypes in microtumors from epithelial breast cells and patient-derived primary metastatic breast cancer cells, mesothelioma cells, and lung cancer xenograft cells. The microtumor models from various patient-derived tumor cells and patient-derived xenograft cells revealed upregulation of tumor-secreted factors, including matrix metalloproteinase-9 (MMP9), fibronectin (FN), and soluble E-cadherin, consistent with clinically reported elevated levels of FN and MMP9 in patient breast tumors compared with healthy mammary glands. Secreted factors in the conditioned media of large microtumors induced a migratory phenotype in nonhypoxic, nonmigratory small microtumors. Subsequent mathematical analyses identified a two-stage microtumor progression and migration mechanism whereby hypoxia induces a migratory phenotype in the initialization stage, which then becomes self-sustained through a positive feedback loop established among the tumor-secreted factors. Computational and experimental studies showed that inhibition of tumor-secreted factors effectively halts microtumor migration despite tumor-to-tumor variation in migration kinetics, while inhibition of hypoxia is effective only within a time window and is compromised by tumor-to-tumor variation, supporting our notion that hypoxia initiates migratory phenotypes but does not sustain it. In summary, we show that targeting temporal dynamics of evolving microenvironments, especially tumor-secreted factors during tumor progression, can halt tumor migration. Significance: This study uses state-of-the-art three-dimensional microtumor models and computational approaches to highlight the temporal dynamics of tumor-secreted microenvironmental factors in inducing tumor migration.
UR - http://www.scopus.com/inward/record.url?scp=85066487094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066487094&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-18-3151
DO - 10.1158/0008-5472.CAN-18-3151
M3 - Article
C2 - 30952634
AN - SCOPUS:85066487094
SN - 0008-5472
VL - 79
SP - 2962
EP - 2977
JO - Journal of Cancer Research
JF - Journal of Cancer Research
IS - 11
ER -